Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).

被引：0
|
作者：
Ferris, Robert L.
Gooding, William E.
Chiosea, Simion I.
Duvvuri, Umamaheswar
Kim, Seungwon
Kubik, Mark
Sridharan, Shaum
Fenton, Moon Jung
Skinner, Heath Devin
Kelly, Zahra Rahman
Li, Housaiyin
Vujanovic, Lazar
Zandberg, Dan Paul
机构：
[1] Hillman Canc Ctr, Pittsburgh, PA USA
[2] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[3] Univ Pittsburgh, Pittsburgh, PA USA
[4] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[5] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[6] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA USA
[7] Univ Pittsburgh, Hillman Canc Ctr, Med Ctr, Pittsburgh, PA USA
[8] UPMC, Hillman Canc Ctr, Dept Radiat Oncol, Pittsburgh, PA USA
[9] Univ Pittsburgh, Med Ctr, Ctr Canc, Pittsburgh, PA USA
[10] UPMC, Hillman Canc Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6018
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
    Hanna, Glenn J.
    O'Neill, Anne
    Shin, Kee-Young
    Wong, Kristine
    Jo, Vickie Y.
    Quinn, Charles T.
    Cutler, Jennifer M.
    Flynn, Michelle
    Lizotte, Patrick H.
    Annino, Donald J., Jr.
    Goguen, Laura A.
    Kass, Jason, I
    Rettig, Eleni M.
    Sethi, Rosh K., V
    Lorch, Jochen H.
    Schoenfeld, Jonathan D.
    Margalit, Danielle N.
    Tishler, Roy B.
    Everett, Peter C.
    Desai, Anupam M.
    Cavanaugh, Megan E.
    Paweletz, Cloud P.
    Egloff, Ann Marie
    Uppaluri, Ravindra
    Haddad, Robert, I
    CLINICAL CANCER RESEARCH, 2022, 28 (03) : 468 - 478
  • [2] Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma
    Zech, Henrike B.
    Moeckelmann, Nikolaus
    Boettcher, Arne
    Muenscher, Adrian
    Binder, Mascha
    Vettorazzi, Eik
    Bokemeyer, Carsten
    Schafhausen, Philippe
    Betz, Christian S.
    Busch, Chia-Jung
    FUTURE ONCOLOGY, 2020, 16 (36) : 3035 - 3043
  • [3] Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.
    Hanna, Glenn J.
    O'Neill, Anne M.
    Jo, Vickie Y.
    Wong, Kristine
    Lizotte, Patrick H.
    Annino, Donald J.
    Goguen, Laura A.
    Kass, Jason I.
    Rettig, Eleni M.
    Sethi, Rosh K. V.
    Lorch, Jochen H.
    Schoenfeld, Jonathan D.
    Margalit, Danielle N.
    Tishler, Roy B.
    Everett, Peter C.
    Desai, Anupam M.
    Paweletz, Cloud P.
    Egloff, Ann Marie
    Uppaluri, Ravindra
    Haddad, Robert I.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
    Luginbuhl, Adam J.
    Johnson, Jennifer M.
    Harshyne, Larry A.
    Linnenbach, Alban J.
    Shukla, Sanket K.
    Alnemri, Angela
    Kumar, Gaurav
    Cognetti, David M.
    Curry, Joseph M.
    Kotlov, Nikita
    Antysheva, Zoya
    Degryse, Sandrine
    Mannion, Kyle
    Gibson, Michael K.
    Netterville, James
    Brown, Brandee
    Axelrod, Rita
    Zinner, Ralph
    Tuluc, Madalina
    Gargano, Stacey
    Leiby, Benjamin E.
    Shimada, Ayako
    Mahoney, My G.
    Martinez-Outschoorn, Ubaldo
    Rodeck, Ulrich
    Kim, Young J.
    South, Andrew P.
    Argiris, Athanassios
    CLINICAL CANCER RESEARCH, 2022, 28 (05) : 915 - 927
  • [5] Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC).
    Uppaluri, Ravindra
    Zolkind, Paul
    Lin, Tianxiang
    Nussenbaum, Brian
    Jackson, Ryan S.
    Rich, Jason
    Pipkorn, Patrik
    Paniello, Randal
    Thorstad, Wade
    Michel, Loren
    Mudianto, Tenny
    Oppelt, Peter John
    Wildes, Tanya Marya
    Dunn, Gavin P.
    Piccirillo, Jay F.
    Kallogjeri, Donna
    Rodig, Scott
    Hagemann, Ian S.
    Chernock, Rebecca
    Adkins, Douglas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
    Joris L. Vos
    Joris B. W. Elbers
    Oscar Krijgsman
    Joleen J. H. Traets
    Xiaohang Qiao
    Anne M. van der Leun
    Yoni Lubeck
    Iris M. Seignette
    Laura A. Smit
    Stefan M. Willems
    Michiel W. M. van den Brekel
    Richard Dirven
    M. Baris Karakullukcu
    Luc Karssemakers
    W. Martin C. Klop
    Peter J. F. M. Lohuis
    Willem H. Schreuder
    Ludi E. Smeele
    Lilly-Ann van der Velden
    I. Bing Tan
    Suzanne Onderwater
    Bas Jasperse
    Wouter V. Vogel
    Abrahim Al-Mamgani
    Astrid Keijser
    Vincent van der Noort
    Annegien Broeks
    Erik Hooijberg
    Daniel S. Peeper
    Ton N. Schumacher
    Christian U. Blank
    Jan Paul de Boer
    John B. A. G. Haanen
    Charlotte L. Zuur
    Nature Communications, 12
  • [7] Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
    Vos, Joris L.
    Elbers, Joris B. W.
    Krijgsman, Oscar
    Traets, Joleen J. H.
    Qiao, Xiaohang
    van der Leun, Anne M.
    Lubeck, Yoni
    Seignette, Iris M.
    Smit, Laura A.
    Willems, Stefan M.
    van den Brekel, Michiel W. M.
    Dirven, Richard
    Karakullukcu, M. Baris
    Karssemakers, Luc
    Klop, W. Martin C.
    Lohuis, Peter J. F. M.
    Schreuder, Willem H.
    Smeele, Ludi E.
    van der Velden, Lilly-Ann
    Tan, I. Bing
    Onderwater, Suzanne
    Jasperse, Bas
    Vogel, Wouter V.
    Al-Mamgani, Abrahim
    Keijser, Astrid
    van der Noort, Vincent
    Broeks, Annegien
    Hooijberg, Erik
    Peeper, Daniel S.
    Schumacher, Ton N.
    Blank, Christian U.
    de Boer, Jan Paul
    Haanen, John B. A. G.
    Zuur, Charlotte L.
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [8] Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck
    Klein, Oliver
    JAMA ONCOLOGY, 2024, 10 (01) : 143 - 144
  • [9] Sequential neoadjuvant chemotherapy (SC) for head and neck squamous cell carcinoma (HNSCC)
    Rixe, O
    Gatineau, M
    Batouche, M
    Raymond, E
    Domenge, C
    Janot, F
    Schwaab, G
    Luboinski, B
    Armand, JP
    ANNALS OF ONCOLOGY, 1998, 9 : 175 - 175
  • [10] Neoadjuvant nivolumab with or without IDO inhibitor in head and neck squamous cell carcinoma (HNSCC): Final pathologic and clinical outcomes.
    Luginbuhl, Adam
    Johnson, Jennifer Maria
    Scott, Elizabeth R.
    Harshyne, Larry
    Flerova, Elizaveta Flerova
    Tuluc, Madalina
    Gargano, Stacey
    Leiby, Benjamin
    Old, Matthew O.
    Seim, Nolan
    Curry, Joseph M.
    Cognetti, David M.
    Argiris, Athanassios
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345